[A study on hepatic arterial infusion for metastatic liver tumor].
This study was designed to evaluate whether hepatic arterial infusion is effective in terms of response rate and survival time of patients with unresectable liver metastasis from colorectal and gastric cancer. In 19 patients with liver metastasis from colorectal cancer, one patient had a CR, 3 had a PR or MR and the remainder showed NC or PD, with an overall response rate of 16.7%. The response rate was higher in men than in women as well as in patients with metachronous liver metastasis. The dose schedules showed no effectiveness in patients with histologically well-differentiated adenocarcinoma. However, there was a statistical difference in survival time according to the response. The overall response rate in 7 patients with liver metastasis from gastric cancer was 42.9% with one patient achieving CR, 2 patients PR and the others PD. As a result, hepatic arterial infusion of antitumor regimen was an effective method for inoperable metastatic liver cancer.
Ishikawa
H
H
Dept. of Surgery, Sasebo General Hospital.
Shimizu
T
T
Nakagoe
T
T
Hirano
T
T
Kusano
H
H
Kajiwara
K
K
Nakamura
Y
Y
Ifuku
M
M
Kawaguchi
A
A
Shiraishi
E
E
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000473:pathology; D015996:Survival Rate
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D016190:Carboplatin; D002945:Cisplatin